Search Results - "Karakashev, Sergey"

Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer by Lin, Jianhuang, Liu, Heng, Fukumoto, Takeshi, Zundell, Joseph, Yan, Qingqing, Tang, Chih-Hang Anthony, Wu, Shuai, Zhou, Wei, Guo, Dajiang, Karakashev, Sergey, Hu, Chih-Chi Andrew, Sarma, Kavitha, Kossenkov, Andrew V., Zhang, Rugang

“…CARM1 is often overexpressed in human cancers including in ovarian cancer. However, therapeutic approaches based on CARM1 expression remain to be an unmet…”
Get full text

EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition by Karakashev, Sergey, Fukumoto, Takeshi, Zhao, Bo, Lin, Jianhuang, Wu, Shuai, Fatkhutdinov, Nail, Park, Pyoung-Hwa, Semenova, Galina, Jean, Stephanie, Cadungog, Mark G., Borowsky, Mark E., Kossenkov, Andrew V., Liu, Qin, Zhang, Rugang

“…In response to DNA double-strand breaks, MAD2L2-containing shieldin complex plays a critical role in the choice between homologous recombination (HR) and…”
Get full text

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer by Karakashev, Sergey, Zhu, Hengrui, Yokoyama, Yuhki, Zhao, Bo, Fatkhutdinov, Nail, Kossenkov, Andrew V., Wilson, Andrew J., Simpkins, Fiona, Speicher, David, Khabele, Dineo, Bitler, Benjamin G., Zhang, Rugang

“…PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here,…”
Get full text

Progress toward overcoming hypoxia-induced resistance to solid tumor therapy by Karakashev, Sergey V, Reginato, Mauricio J

“…Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant…”
Get full text

CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity by Karakashev, Sergey, Zhu, Hengrui, Wu, Shuai, Yokoyama, Yuhki, Bitler, Benjamin G., Park, Pyoung-Hwa, Lee, Jeong-Heon, Kossenkov, Andrew V., Gaonkar, Krutika Satish, Yan, Huihuang, Drapkin, Ronny, Conejo-Garcia, Jose R., Speicher, David W., Ordog, Tamas, Zhang, Rugang

“…CARM1 is an arginine methyltransferase that asymmetrically dimethylates protein substrates on arginine residues. CARM1 is often overexpressed in human cancers…”
Get full text

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors by Karakashev, Sergey, Zhang, Rugang

“…Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited…”
Get full text

The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance by Whelan, Kelly A., Schwab, Luciana P., Karakashev, Sergey V., Franchetti, Lisa, Johannes, Gregg J., Seagroves, Tiffany N., Reginato, Mauricio J.

“…ERBB2, a receptor tyrosine kinase amplified in breast cancer, is a well established regulator of tumor growth in vivo and anoikis resistance leading to…”
Get full text

Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma by Wu, Shuai, Fukumoto, Takeshi, Lin, Jianhuang, Nacarelli, Timothy, Wang, Yemin, Ong, Dionzie, Liu, Heng, Fatkhutdinov, Nail, Zundell, Joseph A, Karakashev, Sergey, Zhou, Wei, Schwartz, Lauren E, Tang, Hsin-Yao, Drapkin, Ronny, Liu, Qin, Huntsman, David G, Kossenkov, Andrew V, Speicher, David W, Schug, Zachary T, Van Dang, Chi, Zhang, Rugang

“…Alterations in components of the SWI/SNF chromatin-remodeling complex occur in ~20% of all human cancers. For example, is mutated in up to 62% of clear cell…”
Get full text

N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance by Fukumoto, Takeshi, Zhu, Hengrui, Nacarelli, Timothy, Karakashev, Sergey, Fatkhutdinov, Nail, Wu, Shuai, Liu, Pingyu, Kossenkov, Andrew V., Showe, Louise C., Jean, Stephanie, Zhang, Lin, Zhang, Rugang

“…Abstract Despite the high initial response rates to PARP inhibitors (PARPi) in BRCA-mutated epithelial ovarian cancers (EOC), PARPi resistance remains a major…”
Get full text

Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2 by Karakashev, Sergey V, Reginato, Mauricio J

“…ERBB2/HER2 belongs to the EGFR-family of receptor tyrosine kinases and its overexpression can promote tumor progression. Breast cancer patients with ERBB2…”
Get full text

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer by Fukumoto, Takeshi, Park, Pyoung Hwa, Wu, Shuai, Fatkhutdinov, Nail, Karakashev, Sergey, Nacarelli, Timothy, Kossenkov, Andrew V., Speicher, David W., Jean, Stephanie, Zhang, Lin, Wang, Tian-Li, Shih, Ie-Ming, Conejo-Garcia, Jose R., Bitler, Benjamin G., Zhang, Rugang

“…ARID1A, a subunit of the SWI/SNF complex, is among the most frequently mutated genes across cancer types. ARID1A is mutated in more than 50% of ovarian clear…”
Get full text

Abstract 3685: The BET inhibitor INCB057643 suppresses ALDH activity by targeting the ALDH1A1 super-enhancer in high-grade serous ovarian cancer by Karakashev, Sergey

“…Abstract The emergence of tumor cells with certain stem-like characteristics such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression…”
Get full text

Abstract 1824: Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2 by Karakashev, Sergey

“…Abstract Breast cancer is one of the most common cancers among women. Many factors are associated with this disease including overexpression/amplification of…”
Get full text

Abstract 716: Targeting Mek-Erk pathway abrogates hypoxia-mediated lapatinib resistance in ErbB2-positive breast cancer cells by Karakashev, Sergey, Reginato, Mauricio

“…Abstract Overexpression/amplification of the tyrosine kinase ErbB2 is often observed in breast cancers. ErbB2 expression activates EGFR signaling pathway…”
Get full text

N 6 -Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance by Fukumoto, Takeshi, Zhu, Hengrui, Nacarelli, Timothy, Karakashev, Sergey, Fatkhutdinov, Nail, Wu, Shuai, Liu, Pingyu, Kossenkov, Andrew V, Showe, Louise C, Jean, Stephanie, Zhang, Lin, Zhang, Rugang

“…Despite the high initial response rates to PARP inhibitors (PARPi) in -mutated epithelial ovarian cancers (EOC), PARPi resistance remains a major challenge…”
Get full text

Abstract A47: Preclinical efficacy of CPI-1688, a novel EZH2 inhibitor, in epithelial ovarian cancer with alterations in the SWI/SNF chromatin remodeling complex by Magno, Elizabeth, Karakashev, Sergey, Mertz, Jennifer, Trojer, Patrick, Zhang, Rugang

“…Abstract Epithelial ovarian cancer is a paradigm for exploring precision medicine in the context of genetic alteration in the SWI/SNF chromatin remodeling…”
Get full text

HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer by Fukumoto, Takeshi, Fatkhutdinov, Nail, Zundell, Joseph A, Tcyganov, Evgenii N, Nacarelli, Timothy, Karakashev, Sergey, Wu, Shuai, Liu, Qin, Gabrilovich, Dmitry I, Zhang, Rugang

“…encoding a subunit of the SWI/SNF complex, is the most frequently mutated epigenetic regulator in human cancers and is mutated in more than 50% of ovarian…”
Get full text

Mouse models of epithelial ovarian cancer for preclinical studies by Karakashev, Sergey, Zhang, Ru-Gang

“…Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related mortality in the developed world. EOC is a heterogeneous disease…”
Get full text

Ovarian cancer: how can resistance to chemotherapy be tackled? by Karakashev, Sergey, Aird, Katherine M

“…Most women with ovarian cancer are diagnosed at late stages of the disease due to limited screening methods and lack of specific symptoms. [...]while the…”
Get full text

Abstract PR15: Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2 by Karakashev, Sergey V., Mauricio, Reginato J.

“…Abstract Breast cancer is one of the most common cancers among women. Many factors are associated with this disease including overexpression/amplification of…”
Get full text